RxDoctor Payments Data

Rachel Nelles

Family · Fargo, NDNPI 1073530515

Payments from drug & device makers

$1,331in general payments, 2019–2025

Across 75 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Dexcom, Inc.$386
  • Medtronic$256
  • Abbott$185
  • Boehringer Ingelheim$134
  • Novo Nordisk$100
  • Sanofi-aventis U.S. LLC$91
  • plus $180 from 7 others

What the payments were for

  • Food & beverage$1,331100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,331 in reported general payments places this provider in the 85th percentile of 496 family providers in North Dakota.

See all family providers in North Dakota

Medicare billing

Part B allowed, 2024
$35,151
Medicare patients
205
Services billed
603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide302$408,060
JardianceEmpagliflozin205$183,299
MounjaroTirzepatide128$149,193
ForteoTeriparatide20$81,371
Tresiba Flextouch U-200Insulin Degludec60$63,256
Tresiba Flextouch U-100Insulin Degludec77$62,643
Soliqua 100-33Insulin Glargine/Lixisenatide58$62,244
FarxigaDapagliflozin Propanediol57$57,229
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog78$46,396
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog18$42,308
JanuviaSitagliptin Phosphate39$33,315
Novolog FlexpenInsulin Aspart103$25,767
TrulicityDulaglutide27$24,824
Fiasp FlextouchInsulin Aspart (Niacinamide)27$24,344
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/728$21,583

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Novolog$100$411,653313 claims
Lilly USA, LLCMounjaro, Forteo, Trulicity, Humalog$22$260,225195 claims
Boehringer IngelheimJardiance$134$183,299205 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$91$62,24458 claims
MerckJanuvia$14$33,31539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 496 family providers in North Dakota.

Other family in Fargo

See the full list for North Dakota

Where these figures come from

Is this you, or does something look wrong? →